Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin

Advances in Therapy

Volumn 30, Issue 4, 2013, Pages 337-353

  Fass, Andrea D ^a   Gershman, Jennifer A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Alogliptin; Combination therapy; Dipeptidyl peptidase 4 inhibitors; Linagliptin; Metformin; Saxagliptin; Sitagliptin; Type 2 diabetes; Vildagliptin

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS METFORMIN; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; LINAGLIPTIN; LINAGLIPTIN PLUS METFORMIN; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ADD ON THERAPY; ANTIDIABETIC ACTIVITY; ARTHRALGIA; BACKACHE; BRONCHITIS; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; CONSTIPATION; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFECTION; INFESTATION; INFLUENZA; INJECTION SITE PRURITUS; LOW DRUG DOSE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARMACEUTICAL CARE; PILL BURDEN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SINUSITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; TREATMENT OUTCOME;

EID: 84878015887     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0023-6     Document Type: Review

References (30)

1. Januvia [package insert]. Northumberland, United Kingdom: Merck & Co., Inc.
2. Onglyza [package insert]. Princeton, New Jersey: Bristol-Myers Squibb; December 2011.
3. Tradjenta [package insert]. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals, Inc; September 2012.
4. Nesina [package insert]. Deerfield, Illinois: Takeda Pharmaceuticals America, Inc; January 2013.
5. Galvus [prescribing information]. Nurenberg, Germany: Novartis Pharmaceuticals.
6. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical Management of Hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193-203.
7. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endoc Pract. 2009;15:540-559.
8. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association; European Association for Study of Diabetes. Management of hyperglycemia in type 2 diabetes: A patient centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;25:1364-1379.
9. CONSORT. CONSORT 2010 checklist of information to include when reporting a randomized trial. Available at: http://www.consort-statement.org/consort- statement/. Accessed Jan 15 2013.
10. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. Reporting of noninferiority and equivalence randomized trials extension of the CONSORT 2010 statement. JAMA. 2012;308:2594-2604.
11. Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:409-418.
12. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13:160-168.
13. Pratley R, Nauck M, Bailey T, et al; 1860-LIRADPP-4 Study Group. One year liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomized, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397-407.
14. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540-549.
15. Bergenstal RM, Wysham C, MacConell L, et al; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet. 2010;376:431-439.
16. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959-969.
17. Gallwitz B, Rosenstock J, Rauch T, et al. 2-Year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet. 2012;380:475-483.
18. Haak T, Meinicke T, Jones R, Weber S, Eynatten M, Woerle Hj. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14:565-574.
19. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65-74.
20. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27:318-326.
21. Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009;11:978-986.
22. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157-166.
23. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Nilsson-Gause I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52 week randomized controlled trial. Int J Clin Pract. 2010;64:1619-1631.
24. Defronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649-1655.
25. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy; a multicentre, randomized, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63:46-55.
26. Takeda Pharmaceuticals. Takeda resubmits new drug applications to the United States Food and Drug Administration for alogliptin and the fixeddose combination alogliptin and pioglitazone. Available at: http://www.takeda.us/ newsroom/press-release-detail.aspx?year=2012&id=244. Accessed Jan 22 2013.
27. US Food and Drug Administration. FDA approves three new drug treatments for type 2 diabetes. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm336942.htm. Accessed Jan 28 2013.
28. Merck. Putting patients first by addressing significant unmet medical needs: update on cardiovascular outcomes study with Januvia. Available at: http://www.merck.com/mrl/clinical-trials/outcomes-study.html. Accessed March 21 2013.
29. ClinicalTrials.gov. Sitagliptin cardiovascular outcome study (0431-082 AM1) (TECOS). Available at: http://clinicaltrials.gov/ct2/show/NCT00790205?term= DPP+4+inhibitors&rank=132. Accessed March 21 2013.
30. ClinicalTrials.gov. Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications (SAVOR-TIMI 53). Available at: http://clinicaltrials.gov/ct2/show/NCT01107886?term= saxagliptin&cond=%22Coronary+Artery+Disease%22&rank=2. Accessed March 21 2013.